ABCG2 and hepatocellular carcinoma: The N-glycosylation inhibitor tunicamycin dramatically suppressed ABCG2 expression, altered its subcellular localization, and reduced the efflux of CDDP by targeting the DPAGT1/AKT/ABCG2 signaling pathway, thus reversing CDDP resistance in HCC [202].